Nanobiotix (NASDAQ:NBTX) Hits New 1-Year High – Should You Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) hit a new 52-week high during trading on Monday . The stock traded as high as $37.87 and last traded at $37.86, with a volume of 12029 shares trading hands. The stock had previously closed at $33.99.

Analyst Ratings Changes

Several brokerages have recently issued reports on NBTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. TD Cowen began coverage on Nanobiotix in a research note on Friday, February 6th. They set a “buy” rating on the stock. Guggenheim lifted their target price on Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Nanobiotix Stock Up 11.4%

The company has a fifty day moving average of $23.90 and a 200 day moving average of $20.35.

Institutional Investors Weigh In On Nanobiotix

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC bought a new position in shares of Nanobiotix in the 4th quarter worth approximately $390,000. Marshall Wace LLP bought a new stake in Nanobiotix during the fourth quarter valued at approximately $220,000. Optiver Holding B.V. purchased a new stake in Nanobiotix during the third quarter valued at approximately $101,000. Finally, Royal Bank of Canada increased its holdings in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.